Ebus-Tbna for Identifying Biomarkers

Kezhong Chen,Fan Yang,Hui Zhao,Zu Li Zhou,Guanchao Jiang,Jun Wang

DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.e21103

IF: 45.3

2012-01-01

Journal of Clinical Oncology

Abstract:e21103 Background: We assessed the usefulness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to detect EGFR AK-ras AALK mutations from malignant mediastinal nodes of patients with NSCLC. Methods: From February 2010 to December 2011 , 52 specimens diagnosed lung adenocarcinoma by EBUS were used for molecular analysis . Needle puncture site for the EBUS was standard 22G needle, once cytology pathology diagnosed adenocarcinoma, at the same site with the conventional needle puncture method to obtain adequate biopsy specimen for further analysis. The tissue was fixed in 10% formalin and stored in -80°C. When histologic diagnosis confirmed adenocarcinoma, the sample was extracted DNA to detect EGFR mutation by both amplification refractory mutation system( ARMS) and mutation enriched method improved by our department. Partial specimens also extracted DNA or RNA to detect K-ras and ALK mutation. Results: All 52 specimens were successfully extracted DNA, 34 were male and 18 were female, mean age of 62.1 years (34 to 79 years). Somatic mutations of the EGFR gene were detected in 25 of 52 cases (48%), 15 cases of exon 19 mutation, 9 cases of exon 21 mutation, and 1 of T790M mutation in ARMS. The result was of slight difference in mutation enriched method. In the patients who requested other biomarkers analysis, 4 had K-ras mutations and 2 had ALK mutations. 6 patients of 25 cases of patients with EGFR mutations had a radical surgery after neoadjuvant chemotherapy, tumor specimens were tested again with EGFR gene mutation, the same result as the preoperative test results. Conclusions: EBUS-TBNA mediastinal lymph node biopsy in the detection of EGFR AK-ras and ALK mutations in tissue samples was feasible, through the highly sensitive methods, higher detection rate was available, the result can be used as evidence of personalized treatment of lung cancer.